ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors
February 16, 2017
Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L. Smith, MD, MBA, has joined the Company’s Board of Directors.
“ProLung is pleased to have the guidance of Dr. Smith as we complete our pivotal trial enrollment and begin positioning the company toward commercialization,” stated Steven Eror, CEO and founder of ProLung. “Her extensive experience as a thought leader in the healthcare space will be of great benefit to our shareholders and patients as we reach significant milestones,” added Todd Morgan, Chairman of the Board.
“I am pleased to be joining ProLung at this exciting moment,” stated Dr. Smith. “I believe there is an urgent need in the practice of pulmonology to assist practitioners with an objective, non-radiating, and non-invasive tool. ProLung’s technology is already approved in Europe and is currently saving lives.”
Dr. Smith serves as Chairman of the Board for MYnd Analytics, is a director of Rockwell Medical and serves as a director of Bioxcel Corporation. She is Chairman of the Board of the Cura Foundation and Stem for Life Foundation. She also serves on the international board of Stanford Health and is Vice President of the STOQ Foundation of the Vatican dedicated to the dialogue between science and faith. Dr. Smith earned her M.D. from Yale University and M.B.A. from the Wharton School of Business.
ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung’s predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the US.
For more information, contact:
Ryan Snow | +1-801-503-9231 | email@example.com